CR-1202 is under clinical development by Conaris Research Institute and currently in Phase III for Unspecified Gastrointestinal Disorders. According to GlobalData, Phase III drugs for Unspecified Gastrointestinal Disorders have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how CR-1202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CR-1202 overview
CR-1202 is under development for the treatment of unspecified gastrointestinal disorders. It is a gut microbiota modulator.
Conaris Research Institute overview
Conaris Research Institute (Conaris) is a biotechnological company that offers preclinical and early clinical development services. The company provides drugs for various inflammatory indications. Its pipeline product candidates includ CR15/01, CR12/01, CR12/02, CR13/01, FE999301 and conaskin tinktur. Conaris offers services such as development of new drugs, physical and chemical characterization, lead optimization, lab scale production and GMP development. It also develops in-house technology platform and a network of associated partners for the requirements of drug development candidates. Conaris is headquartered in Kiel, Schleswig-Holstein, Germany.
For a complete picture of CR-1202’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.